Figure 2.

SERPINA3 and ACT expression in cancer samples and relation to patient survival. (A) Higher expression of SERPINA3 in GBM tissues compared to noncancer as measured by RT-qPCR in samples from the Mayo Clinic Biobank. (B, C) Immunoblot quantification of multiple GBM tissues expressing higher levels of ACT than control samples from Mayo Clinic Biobank. (D) TCGA dataset depicting higher levels of SERPINA3 mRNA in GBM samples. (E) Correlation between increased SERPINA3 mRNA expression and glioma grade (TCGA data). (F) Survival analysis of TCGA dataset on glioma patients reveals that patients with high SERPINA3 expression have significantly worse outcome. *P < .05, **P < .01. ACT, α1-antichymotrypsin; GBM, glioblastoma; TCGA, The Cancer Genome Atlas.